Search the Newsreel

Abbott, Up 14%, Strikes Three-Month High After Boosting 2026 Profit Outlook

Abbott stock surged to a three-month high after the company raised its full-year earnings outlook for 2026. This positive revision follows a strong second-quarter report. The new guidance indicates an adjusted earnings per share of $5.45 to $5.60, an increase of about 4 cents …

Why Abbott Stock Is Reimagining Its Future

Abbott (ABT) is undergoing a significant strategic shift, moving its focus and capital allocation away from its volatile Nutrition segment towards high-margin, innovation-led MedTech and specialized diagnostics. This pivot involves stabilizing the Nutrition segment's margins through strategic pricing despite declining sales, while aggressively expanding …

Is Abbott Laboratories (ABT) Below Fair Value After Its 31% Fall?

Abbott Laboratories (ABT) has experienced a 31% stock price fall over the past year, leading to investor sentiment turning negative. However, both discounted cash flow (DCF) analysis and traditional market multiples suggest the shares are currently trading at a discount. Despite potential risks like …

Abbott Laboratories Sales Rise on Diagnostics Growth

Abbott Laboratories reported higher revenue in the second quarter, primarily driven by increased sales in its diagnostics business. Despite the revenue boost, the company's profit for the quarter fell to $928 million from $1.78 billion in the prior year. Abbott also raised its full-year …

What Investors Don’t Understand About Abbott Laboratories

Abbott Laboratories (ABT) is undervalued by investors who still perceive it as a slow-growth bond proxy, despite significant transformations. The company's medical devices segment, particularly the FreeStyle Libre, is driving strong growth, and a recent $21 billion acquisition of Exact Sciences is set to …

Abbott eleva su previsión de beneficio por acción para 2026

Abbott Boosts 2026 Profit Guidance as Sales Across Business Rise

Abbott Laboratories has increased its 2026 profit guidance following a better-than-expected second quarter. The company now anticipates adjusted earnings per share to be between $5.45 and $5.60, representing a 5-cent improvement at the midpoint. This positive outlook is attributed to strong performance across most …

Is AbbVie (ABBV) Fully Priced Despite Tepkinly Approval And Cash Flow?

AbbVie (ABBV) stock has achieved a 150.7% return over five years, presenting a mixed valuation picture. While a Discounted Cash Flow (DCF) model suggests the stock is undervalued by 46.4% due to strong cash flow and recent Tepkinly approval, market-based multiples, specifically the P/E …

Abbott-Aktie schießt nach Q2-Zahlen hoch: Gewinn bricht ein, FY26-EPS-Prognose steigt

Reasons to Retain Abbott Stock in Your Portfolio for Now

Abbott Laboratories (ABT) is recommended as a stock to retain due to strong performance in its Nutrition business and growth in emerging markets within its Established Pharmaceuticals Division (EPD). However, potential headwinds include currency fluctuations, a dull macroeconomic environment, and increased operating costs. The …

Can Abbott (ABT) Turn Freenome Progress Into a Durable Diagnostics-Led Growth Story?

Abbott Laboratories is set to release its Q2 2026 results, with recent progress in diagnostics, particularly its collaboration with Freenome for blood-based colorectal cancer screening, as a key focus. This development could reshape Abbott's investment narrative towards diagnostics-led growth, helping to offset challenges in …

Aussie Broadband (ASX:ABB) Holds Steady as Investors Watch the Next Growth Phase

AbbVie’s range-top push rests on June’s 87.5M-share breakout, not fresh July volume

ABBV closed within 0.2% of its 52-week high after a 14.9% four-week run, but the latest advance came on 0.9x volume and leaves valuation distance stretched.

Aussie Broadband (ASX:ABB): What Makes This Customer-First Broadband Provider Stand Out From the Crowd?

AbbVie Inc (ABBV) director acquisition adds insider angle to a strong tape

The disclosure gives investors a governance marker as the drugmaker trades with heavier turnover and firm relative performance.

AbbVie Inc (ABBV) gets a 17.0% weekly reset on heavy turnover

The healthcare heavyweight’s latest weekly move sharpened a broader four-week advance, though the trend signal has not yet turned active.

Abbott Laboratories (ABT) Stock Analysis: Potential 23.82% Upside Amid Strong Buy Ratings

ABBN Prognose — Kursziel für 2027

AbbVie Stock Leads 3 Cash Flow Picks Trading Below Estimated Value

Aussie Broadband Shares Give Back Half 2026 Gains To Start Week: What Happened?

Why Aussie Broadband, Coles, EOS, and Santos shares are falling on Monday

Why Aussie Broadband (ASX:ABB) Stock Is Down 4% Today?

AbbVie stock slides to lower edge of recent range as buyers show dominance: weekly outlook

What Is Driving Investor Interest in Aussie Broadband (ASX:ABB) Shares?

Abbott Laboratories stock gains as Norges Bank acquires new institutional position

Aussie Broadband Limited. (ASX:ABB): Telco Challenger Primes for Massive Structural Breakout

Should Aussie Broadband’s Enterprise Pivot and Fibre Expansion Require Action From Aussie Broadband (ASX:ABB) Investors?

Is Aussie Broadband (ASX:ABB) Quietly Repricing? ABB Moves on Volume

Abbott Laboratories (ABT) Stock Analysis: Tapping Into A 35.73% Potential Upside

Abbott Laboratories, Coca-Cola, and Walmart: Top Recession-Proof Stocks for 2026 - News and Statistics

Sohn Hong Kong 2026 - CloudAlpha's Chris Wang Says This Supply-Chain Bottleneck Stock Could Triple By 2030

Why is Abbott Laboratories stock down today?

AMD posts Q1 2026 data center revenue of $5.8bn, forecasts $120bn server CPU income by 2030

Abbott stock tumbles below key moving averages as sellers dominate momentum: weekly outlook

ABBVIE ($ABBV) Releases Q1 2026 Earnings

Lobbying Update: $180,000 of ABBVIE INC. lobbying was just disclosed